Compare LEE & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEE | MXCT |
|---|---|---|
| Founded | 1890 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.6M | 155.8M |
| IPO Year | 2025 | 2021 |
| Metric | LEE | MXCT |
|---|---|---|
| Price | $7.00 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.11 |
| AVG Volume (30 Days) | 33.2K | ★ 1.6M |
| Earning Date | 11-25-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $543,955,000.00 | $33,026,000.00 |
| Revenue This Year | $4.44 | N/A |
| Revenue Next Year | N/A | $15.53 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.34 | $0.64 |
| 52 Week High | $11.88 | $1.81 |
| Indicator | LEE | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 55.24 | 40.00 |
| Support Level | $6.69 | $1.02 |
| Resistance Level | $8.79 | $1.27 |
| Average True Range (ATR) | 0.41 | 0.16 |
| MACD | 0.11 | -0.04 |
| Stochastic Oscillator | 84.50 | 12.50 |
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.